Investor center

Stay up to date with BlinkLab's ASX announcements, corporate updates, and latest clinical and regulatory progress.

ASX

Exchange

BB1

Ticker Code

$...

Share Price

$...

Market Capitalisation

ASX BB1 Historical Share Price

Select date range:

Autism evaluations depend heavily on clinical observation, which is inherently subjective and leads to variability across clinicians and sites.

BlinkLab is changing that by introducing an AI-powered, smartphone-based diagnostic tool with objective, reflex-based measures that reduce reliance on observation-based assessment alone. With this diagnostic aid, designed for comfortable at-home use, specialists can identify autism much earlier and more accurately.

Why invest in BlinkLab?

BlinkLab combines proprietary technology, clinical validation studies, and a clear, staged regulatory pathway to commercialization, addressing an unmet medical need in autism assessment.

Read more
Smiling man with dark curly hair and beard wearing a black button-up shirt standing indoors near a window.

Henk-Jan Boele, MD, PhD

Managing Director & Chief Executive Officer | Co-Founder

"For me, it's gratifying to apply neuroscience for improving autism and ADHD diagnosis and care."

Dr. Henk-Jan Boele, co-founder of BlinkLab, leads a team of neuroscientists, medical doctors, and software developers to bring this mission to life. Founded as a Princeton University startup in 2021, BlinkLab went public on the ASX (ASX:BB1) in April 2024 and is now seeking FDA clearance for its first two diagnostic products:

BlinkLab Dx1 – Diagnostic Aid Supporting Autism Assessment

FDA 510(k) Regulatory Program Currently Underway

BlinkLab Dx2 – Diagnostic Aid Supporting ADHD Assessment

Clinical Feasibility Studies Currently in Preparation

BlinkLab's technology
Watch the interview
View regulatory pipeline

ASX announcements

Latest ASX announcements and company updates, including research milestones, commercial progress, and corporate actions.

  • Loading...

    Loading...